


# SYNTHESIS OF POLYFLUOROKETONES CONTAINING AN INDOLE RING AS INHIBITORS OF HUMAN Ca<sup>2+</sup>- INDEPENDENT PHOSPHOLIPASE A<sub>2</sub>

<u>Anneta Smyrniotou</u><sup>a</sup>, Violetta Constantinou- Kokotou<sup>a</sup>, George Kokotos<sup>b</sup> <sup>a</sup>Chemical Laboratories, Agricultural University of Athens, Athens, Greece; <sup>b</sup>Department of Chemistry, University of Athens, Athens, Greece

### **Introduction**

Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) enzymes catalyze the hydrolysis of the sn-2 ester bond of glycerophospholipids producing free fatty acids and lysophospholipids.<sup>1</sup> The main representative of these fatty acids is arachidonic acid, which can be transformed into eicosanoids (prostaglandins, leukotriens, etc) by the action of other enzymes. Lysophospholipids are precursors for other bioactive compounds, such as platelet-activating factor (PAF). PAF and eicosanoids constitute basic mediators of inflammation and other pathophysiological routes. In the superfamily of PLA<sub>2</sub> enzymes, three are the predominant groups found in human tissues; the cytosolic PLA<sub>2</sub> (cPLA<sub>2</sub>), the calcium-independent PLA<sub>2</sub> (iPLA<sub>2</sub>) and the secreted PLA<sub>2</sub> (sPLA<sub>2</sub>).<sup>1</sup> We have recently demonstrated that Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> (GVIA iPLA<sub>2</sub>) plays a key-role in experimental autoimmune encephalomyelitis and that GVIA iPLA, is a novel target for the development of new therapies for multiple sclerosis.<sup>2</sup> A series of fluoroketones of the general structure 1 has been presented as iPLA<sub>2</sub> inhibitors and the structure-activity relationship has been evaluated.<sup>3,4</sup> Polyfluoroketones **FKGK11** and **FKGK18** proved to be potent and selective inhibitors of GVIA iPLA<sub>2</sub> (Table 1). Therefore, to extend this research, we synthesized a variety of polyfluoroketones containing an indole ring and a four carbon atom chain between the ring and the polyfluoroketone group.






3a,b


 $CH_3$ 

b




*Reagents and conditions*: a) DMF,  $(COCl)_2$ , NaOH 9N, H<sub>2</sub>O, b) TsCl, NaOH, CH<sub>2</sub>Cl<sub>2</sub>, r.t. to 35 °C, c) NaH, CH<sub>3</sub>I, THF.

# **Scheme 2**: Synthesis of polyfluoroketones



# **Synthesis**

Indole-3-carboxaldehyde (2) was obtained from indole using the Vilsmeier - Haack reaction and then it was protected with the tosyl or the methyl group (Scheme 1). These two protected aldehydes along with commercially available indole-5-carboxaldehyde underwent a Horner – Wadsworth – Emmons reaction with triethyl-4phosphonocrotonate in the presence of a strong base (1,1,3,3tetramethyl guanidine or NaH) to produce the corresponding unsaturated esters 4a-c (Scheme 2). After catalytic hydrogenation, we received the saturated esters **5a-d**; in the case of ester **5d** the indole ring was also hydrogenated along with the double bonds. After saponification with NaOH 1N in ethanol, we acquired the corresponding carboxylic acids **6a-d** which were converted to acyl chlorides with the method of oxalyl chloride/DMF. In situ, the acyl chlorides were treated with pyridine and trifluoroacetic anhydride or pentafluoropropionic anhydride to provide the trifluoromethyl ketone 8d, and pentafluoroethyl ketones 7a-c. In the case of pentafluoroethyl ketone 7c the reaction conditions of the last step were in consistency with the Vilsmeier – Haack reaction and as a result we obtained the aldehyde derivative (Scheme 3).



## **Conclusion**

Five novel polyfluoroketones were synthesized containing an indole ring and the evaluation of their inhibitory activity is in progress.

#### References

#### Acknowledgments

This research has been co-financed by the European Union (European Social Fund – ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program: Heracleitus II. Investing in knowledge society through the European Social Fund. 1. Dennis, E.A.; Cao, J.; Hsu, Y.-H.; Magrioti, V.; Kokotos, G. *Chem. Rev.* **2011**, *111*, 6130–6185.

- 2. Kalyvas, A.; Baskakis, C.; Magrioti, V.; Constantinou-Kokotou, V.; Stephens, D.; Dennis, E. A.; Kokotos G.; David, S. *Brain* **2009**, *132*, 1221-1235.
- 3. Baskakis, C.; Magrioti, V.; Cotton, N.; Stephens, D.; Constantinou-Kokotou, V.; Dennis, E.A.; Kokotos, G. J. Med. Chem. 2008, 51, 8027–8037.
- 4. Kokotos, G.; Hsu, Y.-H.; Burke, J. E.; Baskakis, C.; Kokotos, C.G.; Magrioti, V.; Dennis, E. A. J. Med. Chem. **2010**, *53*, 3602-361.

